Tokyo, July 10 (Jiji Press)–Japan is expected to lower the price of lecanemab, an Alzheimer’s drug codeveloped by Japanese drugmaker Eisai Co. and Biogen Inc. of the United States, following a health ministry panel’s report citing its low cost-effectiveness. Based on the assessment report, the ministry is expected to cut the official price of the drug by up to 15 pct from the current level…
Tokyo, July 10 (Jiji Press)–Japan is expected to lower the price of lecanemab, an Alzheimer’s drug codeveloped by Japanese drugmaker Eisai Co. and Biogen Inc. of the United States, following a health ministry panel’s report citing its low cost-effectiveness. Based on the assessment report, the ministry is expected to cut the official price of the drug by up to 15 pct from the current level…
Leave a comment